3SBio Discontinues NuLeusin; Sinovac To Benefit From Government Vaccine Supply Plan: China Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
Executive Summary
China's generic pharma companies suffered a slowdown in Q3, but biotech companies saw healthy growth.
You may also be interested in...
From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
SHANGHAI - 3SBio Inc.'s success with a biosimilar of Amgen Inc.'s erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government
With Limits Created By China's New Pharmacopoeia, What's Next For Vaccine Manufacturers?
SHANGHAI - China is expected to be the world's largest vaccine market by 2020, and every vaccine maker is trying to increase their presence to gain market share. However, the new Chinese Pharmacopoeia might put these efforts to an end and almost all vaccines from multinational companies may have to withdraw from China if they fail to comply with new standards
China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome
BEIJING - In a step toward lifting a longstanding veil on the drug review process in China, the State FDA has for the first time issued a public outline of the range and types of medicines approved by regulators last year